Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept vs placebo in SAPHO syndrome
2024-516919-25-00Phase 3Authorised
- Sponsor
- National Institute of Geriatrics, Rheumatology and Rehabilitation
- Start
- Oct 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in SAPHO syndrome (SAPHO) comparing Etanercept with Placebo (2 arms). Primary endpoint: Patient-assessed disease activity and pain improvement at 12 weeks. Planned start Oct 2024; status: authorised.
02
Drugs
etanercept
03
Conditions
SAPHO syndrome (SAPHO)
Beyond the preview
Go deeper on 2024-516919-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516919-25-00.